{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T01:49:12Z","timestamp":1776995352997,"version":"3.51.4"},"reference-count":8,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.ijid.2020.05.072","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T11:55:13Z","timestamp":1590494113000},"page":"500-502","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"special_numbering":"C","title":["Three cases of treatment with nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy"],"prefix":"10.1016","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4783-8110","authenticated-orcid":false,"given":"Sukbin","family":"Jang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4664-7048","authenticated-orcid":false,"given":"Ji-Young","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2020.05.072_bib0005","series-title":"Nafamostat","author":"Drugbank","year":"2020"},{"key":"10.1016\/j.ijid.2020.05.072_bib0010","article-title":"Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation","author":"Gao","year":"2020","journal-title":"medRxiv"},{"issue":"1","key":"10.1016\/j.ijid.2020.05.072_bib0015","first-page":"1","article-title":"The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak\u2013an update on the status","volume":"7","author":"Guo","year":"2020","journal-title":"Mil Med Res"},{"key":"10.1016\/j.ijid.2020.05.072_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.ijid.2020.05.072_bib0025","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3390\/v12040372","article-title":"Virology, Epidemiology, Pathogenesis, and Control of COVID-19","volume":"12","author":"Jin","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.ijid.2020.05.072_bib0030","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.16727","article-title":"Thromboembolic risk and anticoagulant therapy in COVID-19 patients: Emerging evidence and call for action","author":"Kollias","year":"2020","journal-title":"Br J Haematol."},{"issue":"3","key":"10.1016\/j.ijid.2020.05.072_bib0035","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"issue":"11","key":"10.1016\/j.ijid.2020.05.072_bib0040","doi-asserted-by":"crossref","first-page":"6532","DOI":"10.1128\/AAC.01043-16","article-title":"Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay","volume":"60","author":"Yamamoto","year":"2016","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971220303799?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971220303799?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:54:37Z","timestamp":1761119677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971220303799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":8,"alternative-id":["S1201971220303799"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2020.05.072","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Three cases of treatment with nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2020.05.072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}